AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
triamcinolone hexacetonide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| steroids not used as glucocorticosteroids | 4976 | 5611-51-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
synthetic glucocorticoid analog used for anti-inflammatory effects in disorders of many organ systems
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,ZAP70 | 37 | |||
| kinase-selectivity-class | GRK2 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 29, 1969 | FDA | SANDOZ |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Human antichimeric antibody positive | 364.87 | 179.25 | 60 | 2532 | 1726 | 90624129 |
| Body height below normal | 346.36 | 179.25 | 59 | 2533 | 2109 | 90623746 |
| Drug specific antibody | 271.27 | 179.25 | 49 | 2543 | 2463 | 90623392 |
| Polyarthritis | 259.30 | 179.25 | 67 | 2525 | 18283 | 90607572 |
| Bone density decreased | 233.73 | 179.25 | 61 | 2531 | 17284 | 90608571 |
| Adrenal insufficiency | 226.86 | 179.25 | 67 | 2525 | 29854 | 90596001 |
| Antibody test positive | 200.18 | 179.25 | 39 | 2553 | 2950 | 90622905 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Human antichimeric antibody positive | 384.12 | 162.96 | 61 | 2595 | 1681 | 110584962 |
| Body height below normal | 358.97 | 162.96 | 59 | 2597 | 2025 | 110584618 |
| Polyarthritis | 278.77 | 162.96 | 69 | 2587 | 18894 | 110567749 |
| Drug specific antibody | 274.00 | 162.96 | 49 | 2607 | 2779 | 110583864 |
| Bone density decreased | 249.03 | 162.96 | 61 | 2595 | 15981 | 110570662 |
| Adrenal insufficiency | 215.36 | 162.96 | 67 | 2589 | 42323 | 110544320 |
| Antibody test positive | 211.58 | 162.96 | 40 | 2616 | 3080 | 110583563 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA MoA | N0000175450 | Corticosteroid Hormone Receptor Agonists |
| FDA EPC | N0000175576 | Corticosteroid |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D005938 | Glucocorticoids |
| MeSH PA | D006728 | Hormones |
| CHEBI has role | CHEBI:35472 | anti-inflammatory drug |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50177 | dermatologic drug |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
| CHEBI has role | CHEBI:50857 | anti-allergic agent |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:77715 | nasal decongestant |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Lichen planus | indication | 4776004 | DOID:9201 |
| Keloid scar | indication | 33659008 | |
| Lichen simplex chronicus | indication | 53891004 | |
| Necrobiosis lipoidica diabeticorum | indication | 56391002 | |
| Alopecia areata | indication | 68225006 | DOID:986 |
| Discoid lupus erythematosus | indication | 200938002 | |
| Idiopathic thrombocytopenic purpura | contraindication | 32273002 | DOID:8924 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.08 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glucocorticoid receptor | Nuclear hormone receptor | AGONIST | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| I7GT1U99Y9 | UNII |
| D00985 | KEGG_DRUG |
| 4017601 | VUID |
| N0000179269 | NUI |
| 4017599 | VANDF |
| 4017601 | VANDF |
| C0077004 | UMLSCUI |
| CHEBI:9670 | CHEBI |
| CHEMBL1200878 | ChEMBL_ID |
| 21826 | PUBCHEM_CID |
| 1907 | INN_ID |
| C005900 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10759 | RXNORM |
| 354456 | MMSL |
| 4582 | MMSL |
| 5613 | MMSL |
| 5616 | MMSL |
| d00620 | MMSL |
| 002188 | NDDF |
| 002191 | NDDF |
| 116594009 | SNOMEDCT_US |
| 412524002 | SNOMEDCT_US |
| 6028009 | SNOMEDCT_US |
| C0040864 | UMLSCUI |
| DB00620 | DRUGBANK_ID |
| 31307 | PUBCHEM_CID |
| 755 | INN_ID |
| D014221 | MESH_DESCRIPTOR_UI |
| CHEBI:9667 | CHEBI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Hexatrione2% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59137-570 | INJECTION, SUSPENSION | 40 mg | INTRA-ARTICULAR | Unapproved drug for use in drug shortage | 3 sections |